FY2027 Earnings Estimate for NVO Issued By Erste Group Bank

Key Points

• Erste Group Bank slightly lowered Novo Nordisk’s FY2027 EPS estimate to $3.27 from $3.29, which is still below the broader consensus estimate of $3.43.
• Analyst sentiment on Novo Nordisk remains cautious overall, with the stock carrying an average “Hold” rating and a consensus target price of $65.56.
• The company recently reported quarterly EPS of $1.03 on $10.85 billion in revenue, while investors continue to watch momentum in Wegovy and other GLP-1 products amid competition and pricing pressure.

Novo Nordisk A/S (NYSE:NVO - Free Report) - Equities researchers at Erste Group Bank decreased their FY2027 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research note issued to investors on Tuesday, May 5th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $3.27 per share for the year, down from their prior forecast of $3.29. The consensus estimate for Novo Nordisk A/S's current full-year earnings is $3.43 per share.

Several other equities analysts have also issued reports on the company. Citigroup assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a "neutral" rating for the company. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. Morgan Stanley upgraded shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price objective for the company in a report on Tuesday, March 3rd. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 target price for the company. Finally, TD Cowen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 target price on the stock. in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Trading Down 0.1%

NYSE:NVO opened at $46.02 on Monday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a market capitalization of $205.47 billion, a price-to-earnings ratio of 10.80, a PEG ratio of 4.14 and a beta of 0.77. The business's 50-day moving average price is $38.71 and its two-hundred day moving average price is $46.97.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in NVO. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $25,000. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth $25,000. Scarborough Advisors LLC acquired a new position in Novo Nordisk A/S during the first quarter worth $26,000. WealthCollab LLC grew its position in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after purchasing an additional 260 shares in the last quarter. Finally, American National Bank & Trust bought a new position in Novo Nordisk A/S in the fourth quarter valued at $28,000. 11.54% of the stock is owned by institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.